Will the Phase 2 trial "LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer" reach primary completion on or before May 30, 2027?

Resolves Yes if ClinicalTrials.gov record NCT05886439 (Cancer Institute and Hospital, Chinese Academy of Medical Sciences) shows an actual primary completion date on or before May 30, 2027. Registered date at generation: May 30, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By May 30, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.